Moderate Weight Loss Helps Reduce Risk Of Osteoarthritis In The Knee, Maintaining Weight Provides No Benefit
Here's another good reason to lose even a moderate amount of weight: it could reduce your risk of developing osteoarthritis in your knees. People who are overweight and lose just 5 percent of their weight are less likely to develop osteoarthritis of the knee, or knee OA, compared to people who gain weight, according to data from a large ongoing study by the Thurston Arthritis Research Center at the University of North Carolina at Chapel Hill School of Medicine. "We hear a lot of messages about how obesity affects cardiovascular disease and diabetes, but arthritis is often overlooked, " says Lauren Abbate, a third-year medical student at UNC and lead investigator of the knee OA paper, presented Monday, Oct. 19, 2009, at the American College of Rheumatology scientific meeting in Philadelphia. "OA is painful and debilitating. Effective treatments are limited and there's not a cure. But if we can get people to lose weight we may reduce their risk and reduce the pain and disability associated with this condition, " Abbate says.
After carrying out the first randomized placebo-controlled study on the use of magnetic and copper bracelets and wrist straps for relieving the pain of arthritis, researchers in the UK concluded that they were ineffective. The study was led by Stewart Richmond, a Research Fellow in the Department of Health Sciences at the University of York, and was published online on 12 October in the journal Complementary Therapies in Medicine. Richmond's team included colleagues from the universities of Hull, Durham, and the NHS. Magnetic and copper bracelets are used all over the world by people with various chronic musculoskeletal disorders to help reduce pain. The industry is growing worldwide and annual sales for devices that incorporate some kind of magnet for therapeutic purposes now total around 4 billion US dollars. Previous studies have suggested that such devices reduce pain associated with arthritis and similar conditions, but Richmond told the media that: "This is the first randomised controlled trial to indicate that copper bracelets are ineffective for relieving arthritis pain.
Phase III Study Showed Two Years Of ACTEMRA R tocilizumab Inhibited Progression Of Joint Damage And Improved Disease Remission
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced two-year results from a Phase III study, which showed that people with rheumatoid arthritis (RA) who received either a 4 mg/kg or 8 mg/kg dose of ACTEMRA® (tocilizumab), in combination with methotrexate, had no progression of joint damage, (75 and 83 percent, respectively, as assessed by radiograph) compared with people who received methotrexate alone (66 percent). The overall safety profile of ACTEMRA was consistent across all global clinical studies. The study, known as LITHE, will be featured as an oral presentation during the American College of Rheumatology (ACR) Annual Scientific Meeting along with results from two additional studies evaluating the long-term use of ACTEMRA in people with RA. The LITHE study also showed that people who received either dose of ACTEMRA plus methotrexate showed significant improvement in physical function, compared with people who received methotrexate plus placebo, as measured by the mean area under the curve (AUC) of the Health Assessment Questionnaire Disability Index (HAQ-DI)i change from baseline.
Medical researchers will report findings (Oct. 19) that demonstrate that injecting the protein lubricin into knee joints can dramatically reduce cartilage degeneration. The discovery by scientists at Biomodels, a preclinical drug research organization, and Lubris, a Massachusetts-based startup company, could result in a new therapy for individuals at risk for osteoarthritis, researchers said. The study, by Gregory D. Jay, MD, PhD, a Professor of Emergency Medicine and Biomedical Engineering at Rhode Island Hospital and Brown University, will be presented Monday morning at the American College of Rheumatology/Association of Rheumatology Health Professionals Conference. In the study performed at Biomodels, the transection of the ACL (anterior cruciate ligament) in untreated rats resulted in progressive degeneration of the knee joints and the articular cartilage. In rats treated with recombinant human lubricin, however, the degeneration was far less pronounced, indicating that treatment with lubricin can slow the development of osteoarthritis following traumatic joint injury, and possibly reverse the process, according to Dr.
New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting. "New data demonstrate sustained efficacy of golimumab dosed every four weeks in patients with RA who were previously treated with anti-TNF agents, " said Dr. Jonathan Kay, Professor of Medicine and Director of Clinical Research in the Rheumatology Division at the University of Massachusetts Medical School in Worcester, Massachusetts and lead study investigator. Findings from the GOlimumab After Former anti-TNF Therapy Evaluated in RA (GO-AFTER) study demonstrated that patients with RA previously treated with adalimumab, etanercept or infliximab responded to, and maintained response to, SIMPONI through one year.
Genentech And Biogen Idec Announce Positive Results From First Phase III Trial Of Ocrelizumab In Rheumatoid Arthritis
Genentech, Inc. a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today a Phase III study (STAGE) of the investigational humanized anti-CD20 monoclonal antibody ocrelizumab given in combination with methotrexate (MTX) met its primary endpoint of improving signs and symptoms (as measured by American College of Rheumatology or ACR20 response) in rheumatoid arthritis (RA) patients who had an inadequate response to MTX at both 24 and 48 weeks. Genentech and Biogen Idec continue to analyze the study results and plan to submit the data for presentation at an upcoming medical meeting. "These results are significant because they are the first data from a large Phase III trial to show that a humanized antibody targeted at B-cells improves the signs and symptoms of rheumatoid arthritis, " said Hal Barron, M.D., executive vice president, Global Development and chief medical officer, Genentech. "These results build on earlier findings from our broad clinical program aimed at developing medicines to help people living with rheumatoid arthritis.
Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced favorable safety and efficacy data following administration of a second course (R2) of re-treatment with 800 mg of TRU-015 for rheumatoid arthritis (RA). These data are the latest results from the ongoing open-label re-treatment portion of the Phase 2b (15002) RA study of TRU-015. Pfizer Inc. and Trubion are collaborating on the development of TRU-015 for the treatment of autoimmune and inflammatory diseases, including RA. Data from the open-label re-treatment phase of the Phase 2b study demonstrate that repeat administration with TRU-015 is generally well-tolerated and results in sustained improvement in the signs and symptoms of RA. Results were presented at the 2009 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (AHRP) Annual Scientific Meeting in Philadelphia. TRU-015 is Trubion's lead Small Modular Immunopharmaceutical (SMIP) product candidate directed against CD20+ B-cells. The Phase 2b trial is a double-blind, placebo-controlled, randomized study that is designed to evaluate the safety, tolerability, pharmacodynamics (PD), pharmacokinetics (PK) and clinical activity of repeat doses of TRU-015.
AstraZeneca (NYSE: AZN) and POZEN Inc. (Nasdaq: POZN) announced pivotal data from two POZEN clinical trials that were presented at the American College of Rheumatology (ACR) 2009 Annual Scientific Meeting in Philadelphia, PA. The data demonstrated that patients at risk for developing NSAID-associated gastric ulcers taking VIMOVO(TM) (naproxen/esomeprazole magnesium, formerly known as PN 400) experienced significantly fewer endoscopically confirmed gastric ulcers (GU) compared with patients taking enteric-coated (EC) naproxen (500 mg) alone. Data from study PN400-301 showed a 4.1% incidence of GU in patients taking VIMOVO, compared to 23.1% among patients taking EC naproxen (p<0.001). Study PN400-302 showed a 7.1% incidence of GU among patients taking VIMOVO, compared to 24.3% with EC naproxen (p<0.001). VIMOVO is a fixed-dose combination of enteric-coated naproxen, a non-steroidal anti-inflammatory drug (NSAID) and immediate release esomeprazole, a proton pump inhibitor (PPI), under investigation for the treatment of the signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in patients who are at risk of developing NSAID-associated gastric ulcers.
CEL-SCI Presents Data At American College Of Rheumatology Conference Which Suggests That CEL-2000 Has Potential To Slow Damage
CEL-SCI Corporation (NYSE Amex: CVM) announced the presentation of new rheumatoid arthritis data at the American College of Rheumatology's annual meeting in Philadelphia, PA. The data, presented by Dr. Daniel Zimmerman in conjunction with the Company's collaborators from Washington Biotech, Northeastern Ohio Universities College of Medicine and BolderBiopath, indicate that CEL-SCI's rheumatoid arthritis treatment vaccine CEL-2000 acts to prevent or retard the permanent tissue damage caused by rheumatoid arthritis in animals. These statistically significant results were demonstrated by the measurement of four different parameters, suggesting that CEL-2000 appears to block the immune response that causes the autoimmunity which leads to rheumatoid arthritis. The long term results obtained with fewer doses of CEL-2000 vaccine were comparable or better than those seen with Enbrel ® , a leading treatment for people with rheumatoid arthritis. Geert Kersten, Chief Executive Officer of CEL-SCI said, "These results were achieved through a reduction of the inflammatory response that attacks the patient's joints.
The United States Bone and Joint Decade announced an unparalleled program for its 2009 Global Network Conference to be held in Washington, D.C., Wednesday, October 21-Saturday, October 24. The conference will bring together the official Bone and Joint Decade National Action Network representatives from 56 countries, members of the administration, government policy makers, health care providers, patients and patient advocates for a two-day Patient Advocacy Meeting on October 21-22 and the Global Network Conference on October 23-24. The Global Network Conference is a two-day education and strategic planning meeting which will highlight the significant burden of disease posed by musculoskeletal conditions and why raising awareness and engaging in advocacy are important means to advance prevention and treatment. On October 22, there will be a focus on raising awareness of musculoskeletal conditions on Capitol Hill for U.S. delegates, patients and the leadership of USBJD participating organizations.